Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran.
Department of Developmental Biology, University of Science and Culture, Tehran, Iran.
Oncogene. 2019 Aug;38(34):6226-6239. doi: 10.1038/s41388-019-0871-x. Epub 2019 Jul 15.
Pancreatic ductal adenocarcinoma (PDAC) arises through accumulation of multiple genetic alterations. However, cancer cells also acquire and depend on cancer-specific epigenetic changes. To conclusively demonstrate the crucial relevance of the epigenetic programme for the tumourigenicity of the cancer cells, we used cellular reprogramming technology to reverse these epigenetic changes. We reprogrammed human PDAC cultures using three different techniques - (1) lentivirally via induction of Yamanaka Factors (OSKM), (2) the pluripotency-associated gene OCT4 and the microRNA mir-302, or (3) using episomal vectors as a safer alternative without genomic integration. We found that induction with episomal vectors was the most efficient method to reprogram primary human PDAC cultures as well as primary human fibroblasts that served as positive controls. Successful reprogramming was evidenced by immunostaining, alkaline phosphatase staining, and real-time PCR. Intriguingly, reprogramming of primary human PDAC cultures drastically reduced their in vivo tumourigenicity, which appeared to be driven by the cells' enhanced differentiation and loss of stemness upon transplantation. Our study demonstrates that reprogrammed primary PDAC cultures are functionally distinct from parental PDAC cells resulting in drastically reduced tumourigenicity in vitro and in vivo. Thus, epigenetic alterations account at least in part for the tumourigenicity and aggressiveness of pancreatic cancer, supporting the notion that epigenetic modulators could be a suitable approach to improve the dismal outcome of patients with pancreatic cancer.
胰腺导管腺癌 (PDAC) 是通过积累多种遗传改变而发生的。然而,癌细胞也会获得并依赖于特定的癌症表观遗传变化。为了确凿地证明表观遗传程序对癌细胞致瘤性的关键相关性,我们使用细胞重编程技术来逆转这些表观遗传变化。我们使用三种不同的技术——(1) 通过诱导 Yamanaka 因子 (OSKM) 的慢病毒,(2) 多能相关基因 OCT4 和 microRNA mir-302,或 (3) 使用无基因组整合的更安全的附加体载体,对人 PDAC 培养物进行重编程。我们发现,使用附加体载体诱导是重编程原代人 PDAC 培养物以及用作阳性对照的原代人成纤维细胞的最有效方法。成功重编程的证据是免疫染色、碱性磷酸酶染色和实时 PCR。有趣的是,重编程原代人 PDAC 培养物可大大降低其体内致瘤性,这似乎是由于细胞在移植后增强的分化和失去干性所致。我们的研究表明,重编程的原代 PDAC 培养物在功能上与亲本 PDAC 细胞明显不同,导致体外和体内致瘤性大大降低。因此,表观遗传改变至少部分解释了胰腺癌的致瘤性和侵袭性,支持了表观遗传调节剂可能是改善胰腺癌患者不良预后的一种合适方法的观点。